Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Breast Neoplasms 5Prostatic Neoplasms 4Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Non-Hodgkin 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Mycosis Fungoides 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Leukemia, Hairy Cell 3Leukemia 3Hodgkin Disease 3Head and Neck Neoplasms 3Brain Neoplasms 3Blast Crisis 3Melanoma 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

Gemcitabine 83Cisplatin 59pembrolizumab 28Paclitaxel 21Nivolumab 21Carboplatin 21Cystectomy 20Docetaxel 18durvalumab 17atezolizumab 17Magnetic Resonance Spectroscopy 16Specimen Handling 15Radiotherapy 14avelumab 13Mitomycin 13Sunitinib 12Doxorubicin 12Methotrexate 11Fluorouracil 11Vinblastine 10Filgrastim 7BCG Vaccine 7Sorafenib 6Ipilimumab 6Immunoglobulin G 6Disulfides 6Biopsy 6enfortumab vedotin 5cabozantinib 5Trastuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urinary Bladder Neoplasms × Therapeutics × Clear all
NCT07307456 2025-12-29

Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration

Changhai Hospital

Phase 2 Recruiting
31 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡